Innovacell Announces Regular Updates on ICEF15 Trial Progress and Inclusion Numbers

Innovacell's Commitment to Transparency in the ICEF15 Clinical Trial

Innovacell Co. Ltd., a pioneering biopharmaceutical company based in Japan, has officially announced that it will begin providing regular updates on the enrollment numbers of its ongoing international Phase III clinical trial for ICEF15. This initiative marks a significant effort toward enhancing transparency for investors and stakeholders, providing them with timely insights into the development progress of ICEF15.

Background of the ICEF15 Phase III Trial

The ICEF15 trial is crucial for Innovacell, as it represents one of the most advanced product pipelines within the company. Currently, the trial is being conducted across 11 countries in Europe and Japan under the name 'Fidelia Trial.' Innovacell aims to complete patient enrollment by the end of December 2026. Throughout this process, the company has been actively updating stakeholders about the current status, utilizing different communication channels such as financial results and progress videos.

In an effort to provide more immediate and frequent updates, Innovacell will now share bi-weekly reports on enrollment figures based on contract research organization (CRO) data directly on its corporate website. This initiative is particularly notable as innovative biotech firms rarely disclose clinical trial enrollment data at such regular intervals. The intention is to foster a deeper understanding amongst investors regarding the current advancements of the ICEF15 product, aiding them in making informed investment decisions.

First Reporting Date: June 19, 2026
Publication Location URL: Innovacell Updates

Overview of ICEF15

ICEF15 strives to provide a groundbreaking solution for patients suffering from urge fecal incontinence (UFI), utilizing the patient’s own cells for localized muscle repair and regeneration. UFI is characterized by involuntary leakage of stool due to an inability to reach the restroom in time, leading to social and psychological distress for millions of patients, with estimates suggesting around 5 million individuals in Japan alone are affected by this condition.

The primary symptom of urge fecal incontinence involves a sudden urge to defecate that cannot be suppressed. This condition is often linked to a decline in the functionality of the external anal sphincter muscle. Research published in medical journals indicates that a significant portion—over half—of fecal incontinence patients report experiencing urgency as a predominant symptom (source: Japanese Society of Coloproctology).

Innovacell’s Mission

Founded in 2021, Innovacell was established in Japan as a spin-off from the Medical University of Innsbruck in Austria. The company aims to revolutionize regenerative medicine and cellular therapies, focusing on enhancing the quality of life and overall health for patients. Innovacell is dedicated to researching and commercializing regenerative medicine products aimed at treating various types of incontinence, including urge fecal incontinence, overflow fecal incontinence, and stress urinary incontinence.

Currently, Innovacell is conducting the Phase III international clinical trial for ICEF15, aiming to achieve a fundamental treatment for urge fecal incontinence by leveraging the patient’s own cells for localized administration and muscle regeneration.

In addition to ICEF15, Innovacell has successfully completed multiple clinical trials in Europe for its two pipelines: ICEF15 targeting urge fecal incontinence and ICES13 targeting stress urinary incontinence, including late-stage Phase II trials. The company is committed to advancing its research and ultimately improving healthcare solutions for millions of individuals struggling with incontinence issues.